Skip Nav Destination
Issues
1 August 2011
-
Cover Image
Cover Image
![issue cover]()
Three-dimensional structure of the trastuzumab/pertuzumab/HER2 ternary complex. Yellow, orange, and magenta are trastuzumab, pertuzumab, and HER2, respectively. Trastuzumab and pertuzumab bind to HER2 without competing with each other. For further details, please see Yamashita-Kashima and coworkers on page 5060 in this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Editor’s Note
CCR Perspectives in Drug Approval
Molecular Pathways
Review
Perspective
Human Cancer Biology
Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma
Takafumi Kubo; Shinichi Toyooka; Kazunori Tsukuda; Masakiyo Sakaguchi; Takuya Fukazawa; Junichi Soh; Hiroaki Asano; Tsuyoshi Ueno; Takayuki Muraoka; Hiromasa Yamamoto; Yasutomo Nasu; Takumi Kishimoto; Harvey I. Pass; Hideki Matsui; Nam-ho Huh; Shinichiro Miyoshi
Cancer Therapy: Preclinical
Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells
Marianne E. Marshall; Trista K. Hinz; Scott A. Kono; Katherine R. Singleton; Brady Bichon; Kathryn E. Ware; Lindsay Marek; Barbara A. Frederick; David Raben; Lynn E. Heasley
Imaging, Diagnosis, Prognosis
High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Johannes H. Schulte; Hagen S. Bachmann; Bent Brockmeyer; Katleen DePreter; André Oberthür; Sandra Ackermann; Yvonne Kahlert; Kristian Pajtler; Jessica Theissen; Frank Westermann; Jo Vandesompele; Frank Speleman; Frank Berthold; Angelika Eggert; Benedikt Brors; Barbara Hero; Alexander Schramm; Matthias Fischer
Cancer Therapy: Clinical
Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma
Marc A. Weniger; Edgar G. Rizzatti; Patricia Pérez-Galán; Delong Liu; Qiuyan Wang; Peter J. Munson; Nalini Raghavachari; Therese White; Megan M. Tweito; Kieron Dunleavy; Yihong Ye; Wyndham H. Wilson; Adrian Wiestner
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Steven G. DuBois; Suzanne Shusterman; Ashish M. Ingle; Charlotte H. Ahern; Joel M. Reid; Bing Wu; Sylvain Baruchel; Julia Glade-Bender; Percy Ivy; Holcombe E. Grier; Peter C. Adamson; Susan M. Blaney
Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors
Shivaani Kummar; Mark Raffeld; Lamin Juwara; Yvonne Horneffer; Agnes Strassberger; Deborah Allen; Seth M. Steinberg; Annamaria Rapisarda; Shawn D. Spencer; William D. Figg; Xiaohong Chen; Ismail Baris Turkbey; Peter Choyke; Anthony J. Murgo; James H. Doroshow; Giovanni Melillo
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Shanu Modi; Alison Stopeck; Hannah Linden; David Solit; Sarat Chandarlapaty; Neal Rosen; Gabriella D'Andrea; Maura Dickler; Mary E. Moynahan; Steven Sugarman; Weining Ma; Sujata Patil; Larry Norton; Alison L. Hannah; Clifford Hudis
Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation
Danny Rischin; David C. Bibby; Geoff Chong; Gabriel Kremmidiotis; Annabell F. Leske; Clayton A. Matthews; Shirley S. Wong; Mark A. Rosen; Jayesh Desai
Predictive Biomarkers and Personalized Medicine
EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients
Siwen Hu-Lieskovan; Daniel Vallbohmer; Wu Zhang; Dongyun Yang; Alexander Pohl; Melissa J. Labonte; Peter P. Grimminger; Arnulf H. Hölscher; Robert Semrau; Dirk Arnold; Kathrin Dellas; Annelies Debucquoy; Karin Haustermans; Jean-Pascal H. Machiels; Christine Sempoux; Claus Rödel; Matej Bracko; Vaneja Velenik; Heinz-Josef Lenz
p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
Jonathan F. Lara; Ann D. Thor; Lynn G. Dressler; Gloria Broadwater; Ira J. Bleiweiss; Susan Edgerton; David Cowan; Lori J. Goldstein; Silvana Martino; James N. Ingle; I. Craig Henderson; Larry Norton; Eric P. Winer; Clifford A. Hudis; Matthew J. Ellis; Donald A. Berry; Daniel F. Hayes; for the Cancer and Leukemia Group B
Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
David Olmos; Richard D. Baird; Timothy A. Yap; Christophe Massard; Lorna Pope; Shahneen K. Sandhu; Gerhardt Attard; Juliet Dukes; Dionysis Papadatos-Pastos; Philippa Grainger; Stan B. Kaye; Johann S. de Bono
Advertisement
